Location History:
- Balsham, GB (2011)
- Cambridge, GB (2019 - 2023)
Company Filing History:
Years Active: 2011-2023
Title: The Innovative Journey of Mark Bushfield: Advancing Antibody Identification
Introduction: Mark Bushfield is an accomplished inventor based in Cambridge, GB, known for his contributions to the field of antibody identification. With a total of two patents to his name, he has made significant strides in improving the methods available for screening antibodies.
Latest Patents: Mark's latest invention, titled "Antibody identification by lineage analysis," introduces a novel method of screening that enhances the identification of antibodies. The process involves several key steps: obtaining nucleotide sequences for both the heavy and light chain-encoding nucleic acids of a first antibody from an animal; collecting cDNA sequences that represent the antibody repertoire; computationally screening these sequences to find related heavy and light chain sequences; and ultimately testing pairs of these sequences to identify a second antibody that can bind to the same antigen as the first antibody. This innovative methodology represents a significant leap in antibody research.
Career Highlights: Mark Bushfield's career achievements are closely tied to his work at Epitomics, Inc., where he has dedicated himself to research and development in immunology. His focus on antibody technologies has positioned him as a key figure in advancing the understanding and application of antibodies in various therapeutic contexts.
Collaborations: During his career, Mark has collaborated with notable colleagues, including Michael Hadjisavas and Luc Adam. These partnerships enhance the collaborative spirit of research in his field and contribute to the innovative advancements being made at Epitomics, Inc.
Conclusion: Mark Bushfield's expertise and innovative spirit have made a lasting impact on the scientific community, particularly in the realm of antibody identification. As he continues his work at Epitomics, Inc., his contributions will likely lead to further advancements that benefit both research and clinical applications. With his two patents, Mark stands as a testament to the power of innovation in science.